Key result
The Cardiometabolic Disease Staging system strongly predicted diabetes risk, with Stage 3 subjects having a 23.5-fold higher risk than Stage 0 subjects (95% CI 13.7-40.1; P for trend <0.001).
Why the study?
Does the Cardiometabolic Disease Staging (CMDS) system predict the risk of diabetes, all-cause mortality, and CVD mortality?
Cohort
Yes
Does the Cardiometabolic Disease Staging (CMDS) system predict the risk of diabetes, all-cause mortality, and CVD mortality?
Effect estimate: HR 23.5 (95% CI 13.7-40.1)
p-value: p=<0.001
The CMDS system effectively discriminates the risk for diabetes, CVD mortality, and all-cause mortality independent of BMI, providing a useful risk assessment tool.
No takes yet. Share an insight, caveat, or question.
CMDS may refine diabetes risk stratification independent of BMI; leaves open prospective validation for mortality outcomes and practice adoption.
Guo et al. (2013) conducted a cohort in Cardiometabolic disease. Cardiometabolic Disease Staging (CMDS) system vs. Stage 0 (metabolically healthy) was evaluated on Risk for diabetes (HR 23.5, 95% CI 13.7-40.1, p=<0.001). The Cardiometabolic Disease Staging system strongly predicted diabetes risk, with Stage 3 subjects having a 23.5-fold higher risk than Stage 0 subjects (95% CI 13.7-40.1; P for trend <0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: